1. Home
  2. SOWG vs FBIO Comparison

SOWG vs FBIO Comparison

Compare SOWG & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

N/A

Current Price

$2.31

Market Cap

69.9M

ML Signal

N/A

Logo Fortress Biotech Inc.

FBIO

Fortress Biotech Inc.

N/A

Current Price

$1.91

Market Cap

80.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOWG
FBIO
Founded
2010
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.9M
80.4M
IPO Year
2011
2011

Fundamental Metrics

Financial Performance
Metric
SOWG
FBIO
Price
$2.31
$1.91
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.3K
★ 236.1K
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 97.40
EPS
N/A
★ 2.86
Revenue
N/A
★ $63,262,000.00
Revenue This Year
N/A
$24.55
Revenue Next Year
N/A
$43.73
P/E Ratio
★ N/A
$0.70
Revenue Growth
N/A
★ 9.69
52 Week Low
$0.10
$1.83
52 Week High
$15.90
$4.53

Technical Indicators

Market Signals
Indicator
SOWG
FBIO
Relative Strength Index (RSI) 46.28 38.56
Support Level $2.10 $1.83
Resistance Level $2.62 $2.17
Average True Range (ATR) 0.18 0.08
MACD 0.05 0.02
Stochastic Oscillator 82.29 29.00

Price Performance

Historical Comparison
SOWG
FBIO

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About FBIO Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

Share on Social Networks: